MADRIGAL PHARMACEUTICALS, INC. Capital Expenditures Incurred but Not yet Paid
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Capital Expenditures Incurred but Not yet Paid of $2.56 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-07-30
- MADRIGAL PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for the quarter ending 2026-06-30 was -$419.00K.
- MADRIGAL PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for the quarter ending 2026-03-31 was $2.98M.
- MADRIGAL PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for the quarter ending 2025-09-30 was $728.00K.
- MADRIGAL PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for the quarter ending 2025-06-30 was $0.00.
- MADRIGAL PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for fiscal 2019 was $897.00K.
- MADRIGAL PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for fiscal 2017 was $250.00K.
- MADRIGAL PHARMACEUTICALS, INC. capital expenditures incurred but not yet paid for fiscal 2009 was $58.00K.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$419.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $2.56M 10-Q · filed 2026-07-30 | ||
| 2026-03-31 | $2.98M 10-Q · filed 2026-05-06 | |||
| 2025-09-30 | $728.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $728.00K derived: sum of 2 quarters · filed 2026-07-30 | $728.00K 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $0.00 10-Q · filed 2026-07-30 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-06 | |||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-04 | |||
| 2019-12-31 | $897.00K 10-K · filed 2022-02-24 | |||
| 2017-12-31 | $250.00K 10-K · filed 2020-02-26 | |||
| 2009-12-31 | $58.00K 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |